Geographic expansion Curium plans to expand into Japan and China as part of its 2030 oncology-focused nuclear medicine strategy, presenting upsell opportunities with local hospitals, distributors, and government programs in high-growth markets.

Therapy and diagnostics growth With a focus on neuroendocrine tumors and PSMA therapies, there is a clear path to cross-sell radiopharmaceutical diagnostics and therapeutic products to oncology centers seeking integrated imaging and treatment solutions.

Recent acquisitions The acquisition of Abscint SA strengthens Curium’s portfolio in diagnostic imaging agents, creating opportunities for bundled sales, joint marketing, and expanded customer footprints across Europe and beyond.

US market momentum Lutetium Lu177 dotatate launch in the US following favorable patent outcomes indicates growing demand for targeted radiopharmaceuticals and provides avenues for payer conversations, clinical partnerships, and expanding KOL networks.

Infrastructure investments Investments in production lines and cooling infrastructure signal capacity expansion and reliability improvements, enabling higher-volume contracts with hospitals, cancer centers, and radiopharmacy distributors.